{"id":52171,"date":"2023-09-20T09:30:00","date_gmt":"2023-09-20T09:30:00","guid":{"rendered":"https:\/\/medsname.com\/topamac\/"},"modified":"2026-05-01T10:49:12","modified_gmt":"2026-05-01T10:49:12","slug":"topamac","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/topamac\/","title":{"rendered":"Topamac"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — Topamac — topiramate 25 mg \/ 50 mg, multi-indication anticonvulsant<\/h3>\n

Topamac is topiramate 25 mg \/ 50 mg, an anticonvulsant licensed for epilepsy and migraine prophylaxis<\/strong> and used off-label for alcohol use disorder, weight management, and binge-eating disorder<\/strong>. Slow titration (25 mg weekly increments) over 8 weeks limits cognitive side effects (“topa-dopa”). Renal-dose adjusted. Pregnancy risk — oral cleft malformation. Watch for kidney stones, glaucoma, metabolic acidosis.<\/p>\n<\/div>\n

\n\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n

\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n

\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n

\u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n

What is Topamac?<\/h2>\n

Topamac is a multi-indication anticonvulsant containing topiramate 25 mg \/ 50 mg<\/strong> (film-coated tablets), supplied by Cipla. It is licensed in adults and children for partial-onset and generalised tonic-clonic seizures<\/strong> (monotherapy or adjunctive) and for migraine prophylaxis<\/strong>. Off-label evidence supports use in alcohol use disorder, binge-eating disorder, idiopathic intracranial hypertension, essential tremor, and bipolar disorder<\/strong> — though the strongest non-licensed evidence is for AUD (Johnson 2007).<\/p>\n

How topiramate works<\/h2>\n

Topiramate has multiple, complementary CNS actions:<\/p>\n

    \n
  • Sodium-channel blockade<\/strong> — reduces neuronal excitability (anticonvulsant)<\/li>\n
  • GABA-A potentiation<\/strong> at a non-benzodiazepine site — increases inhibitory tone<\/li>\n
  • Glutamate AMPA \/ kainate receptor antagonism<\/strong> — reduces excitatory neurotransmission; thought to be the main mechanism for AUD effect<\/li>\n
  • Carbonic anhydrase inhibition<\/strong> — explains the metabolic acidosis, kidney-stone, and weight-loss side-effect profile<\/li>\n
  • Voltage-dependent calcium channel modulation<\/strong><\/li>\n<\/ul>\n

    The combination of glutamate AMPA antagonism and GABA-A potentiation is thought to dampen the dopaminergic reward circuitry that drives alcohol craving and binge eating — the same pathway naltrexone targets through opioid receptors.<\/p>\n

    How Topamac is used<\/h2>\n

    Slow titration is essential — rapid escalation produces unacceptable cognitive side effects (the “topa-dopa” phenomenon: word-finding difficulty, mental slowing, confusion). Standard 8-week titration:<\/p>\n\n\n\n\n\n\n\n\n\n\n
    \u0395\u03b2\u03b4\u03bf\u03bc\u03ac\u03b4\u03b1<\/th>\nMorning dose<\/th>\nEvening dose<\/th>\nTotal daily<\/th>\n<\/tr>\n<\/thead>\n
    1<\/td>\n\u2014<\/td>\n25 mg<\/td>\n25 mg<\/td>\n<\/tr>\n
    2<\/td>\n25 mg<\/td>\n25 mg<\/td>\n50 mg<\/td>\n<\/tr>\n
    3<\/td>\n25 mg<\/td>\n50 mg<\/td>\n75 mg<\/td>\n<\/tr>\n
    4<\/td>\n50 mg<\/td>\n50 mg<\/td>\n100 mg<\/td>\n<\/tr>\n
    5–8<\/td>\nincrease by 25 mg\/week<\/td>\nincrease by 25 mg\/week<\/td>\nup to 200 mg\/day<\/td>\n<\/tr>\n
    Maintenance<\/td>\nvaries<\/td>\nvaries<\/td>\nvaries by indication (see below)<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n\n
    \u0395\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/th>\nTarget maintenance dose<\/th>\n\u03a3\u03b7\u03bc\u03b5\u03b9\u03ce\u03c3\u03b5\u03b9\u03c2<\/th>\n<\/tr>\n<\/thead>\n
    Migraine prophylaxis<\/td>\n50–100 mg\/day in two divided doses<\/td>\nOften effective at 100 mg; higher doses raise side-effect rate without much extra benefit<\/td>\n<\/tr>\n
    Adult epilepsy (adjunctive)<\/td>\n200–400 mg\/day in two divided doses<\/td>\nUsual maintenance; some patients tolerate up to 1,600 mg\/day<\/td>\n<\/tr>\n
    Alcohol use disorder (off-label)<\/td>\nTitrated to 200–300 mg\/day<\/td>\nOff-label<\/strong> — Johnson 2007 trial used 300 mg target; lower doses (100–150 mg) sometimes effective with fewer cognitive side effects<\/td>\n<\/tr>\n
    Binge-eating disorder (off-label)<\/td>\n200–400 mg\/day<\/td>\nOff-label; FDA-licensed combination phentermine+topiramate exists for weight loss<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Take with or without food. Adequate hydration reduces kidney-stone risk substantially (aim for > 2 L water daily). Once the maintenance dose is reached, treatment is usually continued for at least 6–12 months for AUD, indefinitely for chronic seizure or migraine prophylaxis.<\/p>\n

    Renal-dose adjustment<\/h2>\n\n\n\n\n\n\n\n\n
    eGFR (mL\/min\/1.73 m²)<\/th>\nAdjustment<\/th>\n<\/tr>\n<\/thead>\n
    > 70<\/td>\n\u03a0\u03c1\u03cc\u03c4\u03c5\u03c0\u03bf<\/td>\n<\/tr>\n
    30–70<\/td>\nReduce by 50%<\/strong>; titrate slower<\/td>\n<\/tr>\n
    < 30<\/td>\nReduce by 50%, monitor closely<\/td>\n<\/tr>\n
    Haemodialysis<\/td>\nSupplemental dose post-dialysis (significantly cleared)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Side effects (slow titration is the key to tolerability)<\/h2>\n
      \n
    • Cognitive slowing, word-finding difficulty (“topa-dopa”)<\/strong> — the dose-limiting side effect; reduces with slower titration and lower target dose<\/li>\n
    • Paraesthesia<\/strong> (tingling in fingers and lips) — very common, usually mild; reduced by potassium-rich diet<\/li>\n
    • Weight loss<\/strong> — consistent and substantial (mean ~5% body weight); usually welcome but may be problematic in low-BMI patients<\/li>\n
    • Nephrolithiasis (kidney stones)<\/strong> — ~1.5% risk; carbonic anhydrase inhibition raises urine pH and lowers citrate. Risk reduced by adequate hydration; avoid in patients with stone history if other options exist<\/li>\n
    • Acute angle-closure glaucoma<\/strong> — rare but ophthalmic emergency, usually within first month; eye pain, blurred vision, red eye = stop drug and seek immediate ophthalmology assessment<\/li>\n
    • Metabolic acidosis<\/strong> (low bicarbonate) — mild and asymptomatic in most; check baseline + periodic bicarbonate<\/li>\n
    • Oligohidrosis and hyperthermia<\/strong> — reduced sweating, mainly in children; caution in hot climates<\/li>\n
    • Mood disturbance, depression, suicidal ideation — class signal across anticonvulsants; monitor<\/li>\n
    • Anorexia, taste perversion (carbonated drinks taste flat — classic and reversible)<\/li>\n<\/ul>\n
      Pregnancy risk.<\/strong> Topiramate is associated with a 2–3-fold increased risk of oral clefts<\/strong> (cleft lip \/ cleft palate) when used in the first trimester, and reduced birthweight. Women of childbearing potential require effective contraception<\/strong> — topiramate at > 200 mg\/day reduces oral-contraceptive efficacy via CYP3A4 induction, so a higher-oestrogen pill, IUD, or barrier method is appropriate. If pregnancy is planned, switch to an alternative anticonvulsant (lamotrigine, levetiracetam) before conception. The Antiepileptic Drug Pregnancy Registry continues to monitor outcomes.<\/div>\n

      \u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
      \u03a6\u03ac\u03c1\u03bc\u03b1\u03ba\u03bf \/ \u03ba\u03b1\u03c4\u03b7\u03b3\u03bf\u03c1\u03af\u03b1<\/th>\n\u0391\u03c0\u03bf\u03c4\u03ad\u03bb\u03b5\u03c3\u03bc\u03b1<\/th>\nAction<\/th>\n<\/tr>\n<\/thead>\n
      Oral contraceptives (combined)<\/td>\nReduced efficacy at > 200 mg\/day topiramate<\/td>\nUse higher-oestrogen pill, IUD, or barrier<\/td>\n<\/tr>\n
      Carbamazepine<\/td>\nLowers topiramate level (CYP3A4 induction)<\/td>\nMay need higher topiramate dose<\/td>\n<\/tr>\n
      \u03a6\u03b1\u03b9\u03bd\u03c5\u03c4\u03bf\u0390\u03bd\u03b7<\/td>\nLowers topiramate level; raises phenytoin level slightly<\/td>\nMonitor levels<\/td>\n<\/tr>\n
      Other carbonic anhydrase inhibitors (acetazolamide, zonisamide, dichlorphenamide)<\/td>\nStacked metabolic acidosis and stone risk<\/td>\nAvoid combination<\/td>\n<\/tr>\n
      Lithium<\/td>\nVariable lithium-level changes<\/td>\nMonitor lithium more frequently after dose change<\/td>\n<\/tr>\n
      Valproate<\/td>\nBoth can cause hyperammonaemic encephalopathy<\/td>\nCaution; check ammonia if confusion develops<\/td>\n<\/tr>\n
      \u0391\u03bb\u03ba\u03bf\u03cc\u03bb<\/td>\nCognitive impairment additive; alcohol increases topiramate effect on driving<\/td>\nCounsel patient<\/td>\n<\/tr>\n
      \u039c\u03b5\u03c4\u03c6\u03bf\u03c1\u03bc\u03af\u03bd\u03b7<\/td>\nBoth raise lactate; theoretical lactic-acidosis stacking<\/td>\nMonitor; usually safe<\/td>\n<\/tr>\n
      \u03a5\u03b4\u03c1\u03bf\u03c7\u03bb\u03c9\u03c1\u03bf\u03b8\u03b5\u03b9\u03b1\u03b6\u03af\u03b4\u03b7<\/td>\nRaises topiramate level<\/td>\nMonitor for side effects<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

      Contraindications and special populations<\/h2>\n